Comparative pharmacology of the angiotensin II receptor antagonists

Dzielak, David J.

doi:10.1517/13543784.7.5.741

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Microalbuminuria reflects the cardiovascular outcomes in both diabetic and nondiabetic patients. 10,11 Microalbuminuria reflects local injury to the endothelium and smooth muscles of blood vessels due to continuous shear stress injury. 10 Resulting in changes in concentration of a variety of local cytokines and nitric oxide that lead to cellular proliferation and increased vascular permeability.…”

Section: Introductionmentioning

confidence: 99%

Microalbuminuria as a risk factor for ischemic cerebrovascular diseases in essential hypertension- a case control study.

Hamza Ali Khan,

Saleem Iqbal,

Farooq Ahmed

et al. 2023

TPMJ

View full text Add to dashboard Cite

Objectives: To determine whether Microalbuminuria, is a risk factor for ischemic cerebrovascular diseases, in our patients with essential hypertension. Study Design: Case Control study. Setting: Department of Medical, Khyber Teaching Hospital, Peshawar. Period: 28th July, 2022 till 28th February, 2023. Material & Methods: After taking no objection certificate from Institutional Review and Ethical Board (IREB) as per notification No 738/DME/KMC, all those patients, who were fulfilling our inclusion criteria, got admission to the medical ward, for determination of microalbuminuria, their urine was collected for 24 hours. The patients were divided into two groups, one without cerebrovascular disease (CVD) and other with CVD. Data of all patients was recorded on a predesigned proforma. Results: Amongst the total of 200 patients enrolled, 58(29%) patients’ age was in range of 16-40 years and 142(71%) patients’ age was in range of 41-120 years. Mean age of our patients was 53 years with standard deviation ± 20.12. As far as gender is concerned, 110(55%) patients were males and 90(45%) patients were females. Approximately 83(41.5%) patients had microalbuminuria and 110(58.5%) patients had no microalbuminuria. Only hypertension but no CVD was present in 145(72.5%) patients, while 55(27.5%) patients had hypertension and CVD, 47.47% of these, had microalbuminuria. Conclusion: Amongst the hypertensive patients, microalbuminuria was present in significantly higher number of patients with ischemic Cerebrovascular Disease as compared to patients who had no cerebrovascular disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Microalbuminuria as a risk factor for ischemic cerebrovascular diseases in essential hypertension- a case control study.

Hamza Ali Khan,

Saleem Iqbal,

Farooq Ahmed

et al. 2023

TPMJ

View full text Add to dashboard Cite

show abstract

“…Compared to other classes of antihypertensive agents, the angiotensin receptor blockers (ARBs) appear to have a low potential for drug interactions; however, variations within the class have been detected, mainly due to different affinities for cytochrome P450 (CYP) isoenzymes [12,16,21]. Due to the rapidly growing utilisation of ARBs as antihypertensive agents, the need for combination therapy in this area, and general polypharmacy and metabolic changes in the elderly in our steadily ageing society, drug interactions with this new class deserve specific attention.…”

Section: Introductionmentioning

confidence: 99%

Drug interactions with angiotensin receptor blockers

Böhler¹,

Pittrow

Bramlage

et al. 2005

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Many patients with high blood pressure receive multiple medications for hypertension and other conditions, placing them at risk for adverse drug interactions. Additionally, as the prevalence of hypertension increases with age, factors like greater frailty, comorbidity of the elderly requiring polypharmacy, and reduced hepatic and renal clearance rates for the elimination of drugs increase the likelihood of drug interactions. Angiotensin receptor blockers (ARBs) are the most recent class of agents for the treatment of hypertension. Due to a favourable side effect profile, this class of drugs deserves increased attention. This article reviews drug interactions of ARBs and suggests measures for reducing the risk of adverse events when drugs are co-administered. MEDLINE, EMBASE, Cochrane library, and CINAHL were searched. Reported and likely clinical relevant interactions of ARBs with concomitantly given drugs are summarised in Table 2 and 3. Compared to other classes of antihypertensive agents, the ARBs appear to have a low potential for drug interactions; however, interactions with this class occur and variations within the class have been detected, mainly due to different affinities for cytochrome P450 isoenzymes.

show abstract

“…Relatively recently, ARBs have been developed to provide more complete angiotensin II blockade with the prevention of the vasopressor and proliferative actions of angiotensin II (9,10). Losartan, the first orally active, nonpeptide ARB, has been shown to be effective in controlling blood pressure in hypertensive patients (11,12).…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

Alcocer

Fernández-Bonetti

Campos

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

The efficacy and safety of once-daily telmisartan 80 mg vs. once-daily enalapril 20 mg in the treatment of essential hypertension were evaluated in a multicentre, singleblind, placebo-controlled, randomised trial. In total, 68 patients (49 females, 19 males) with mild-to-moderate hypertension, defined as morning supine systolic blood pressure (SBP) 141-149 mmHg, diastolic blood pressure (DBP) 95-114 mmHg, were enrolled. After a 4-week placebo run-in phase, patients were randomly assigned to treatment with telmisartan or enalapril administered once daily in the morning for 8 weeks. No statistically significant differences were found in the baseline characteristics of patients in either group. Both SBP and DBP were decreased in both treatment groups, but the reductions were statistically different in favour of telmisartan (SBP, p ¼ 0.013; DBP, p ¼ 0.002). The incidence of adverse effects was lower in the telmisartan group, with the absence of cough. In conclusion, telmisartan is more effective and better tolerated than enalapril for the treatment of hypertension and has the advantage that it does not cause cough.

show abstract

Comparative pharmacology of the angiotensin II receptor antagonists

Cited by 5 publications

References 27 publications

Microalbuminuria as a risk factor for ischemic cerebrovascular diseases in essential hypertension- a case control study.

Microalbuminuria as a risk factor for ischemic cerebrovascular diseases in essential hypertension- a case control study.

Drug interactions with angiotensin receptor blockers

Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

Contact Info

Product

Resources

About